Provided by Tiger Trade Technology Pte. Ltd.

PepGen Inc.

1.66
-0.0100-0.60%
Post-market: 1.65-0.0100-0.60%19:58 EDT
Volume:996.55K
Turnover:1.66M
Market Cap:114.73M
PE:-0.78
High:1.78
Open:1.73
Low:1.61
Close:1.67
52wk High:7.80
52wk Low:0.8801
Shares:69.12M
Float Shares:45.78M
Volume Ratio:0.14
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1234
EPS(LYR):-2.1234
ROE:-67.39%
ROA:-36.03%
PB:0.78
PE(LYR):-0.78

Loading ...

PepGen Inc. (PEPG) Receives a New Rating from Oppenheimer

TIPRANKS
·
Feb 25

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and PepGen Inc. (PEPG)

TIPRANKS
·
Feb 25

PepGen Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
Feb 20

PepGen Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 18

PepGen price target raised to $7 from $6 at Guggenheim

TIPRANKS
·
Feb 18

Desert Control AS Appoints David Borah as Chief Financial Officer

Reuters
·
Feb 03

PepGen Inc. Files Initial Statement of Beneficial Ownership for Chief Business & Legal Officer Joseph Vittiglio

Reuters
·
Dec 11, 2025

PepGen Grants Stock Options to New Chief Business and Legal Officer

Reuters
·
Dec 09, 2025

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) to Newly Appointed Chief Business and Legal Officer

THOMSON REUTERS
·
Dec 09, 2025

BRIEF-PepGen Appoints Joseph Vittiglio, Esq., As Chief Business And Legal Officer

Reuters
·
Dec 08, 2025

PepGen Names Joseph Vittiglio Chief Business and Legal Officer

Reuters
·
Dec 08, 2025

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

THOMSON REUTERS
·
Dec 08, 2025

PepGen Inc. (PEPG) Gets a Sell from Bank of America Securities

TIPRANKS
·
Nov 16, 2025

Wedbush Raises Price Target on PepGen to $9 From $8, Keeps Outperform Rating

MT Newswires Live
·
Nov 13, 2025

PepGen price target raised to $20 from $18 at H.C. Wainwright

TIPRANKS
·
Nov 13, 2025

PepGen Inc. Strengthens Financial Position Amid Ongoing Losses

TIPRANKS
·
Nov 13, 2025

PepGen Receives US Patent for Investigational Candidate for Severe Neuromuscular Disease Treatment

MT Newswires Live
·
Nov 12, 2025

PepGen announces issuance of patent for PGN-EDODM1

TIPRANKS
·
Nov 12, 2025

PepGen Inc - Patent Provides Exclusivity for Pgn-Edodm1 in U.S. Until 2042

THOMSON REUTERS
·
Nov 12, 2025

PepGen Q3 EPS $(0.52) Beats $(0.59) Estimate

Benzinga
·
Nov 12, 2025